No recent analyst price targets found for LZAGY.
Latest News for LZAGY
Lonza Group Continues To Leverage Biopharma's Optimization Push
Lonza Group remains a leading CDMO, capitalizing on biopharma's shift to outsourced manufacturing and complex drug production. LZAGY delivered strong H2 results: 17% CDMO revenue growth, 28% EBITDA growth, and margin expansion to 32.8%. Management guides for 11%–12% CDMO growth and EBITDA margins above 32% in 2026, with free cash flow turning positive next year.
Lonza Group AG (LZAGY) Q4 2025 Earnings Call Transcript
Lonza Group AG (LZAGY) Q4 2025 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for LZAGY.
Senate Trading
No Senate trades found for LZAGY.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.